MilliporeSigma
All Photos(2)

Documents

MKI2MAG-94K

Millipore

MILLIPLEX® Mouse Kidney Injury Magnetic Bead Panel 2 - Toxicity Multiplex Assay

The analytes available for this multiplex kit are: Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, Osteopontin (OPN) (for urine samples) or Clusterin, Cystatin C, Lipocalin-2/NGAL, Osteopontin (OPN) (for serum/plasma samples).

All Photos(2)
eCl@ss:
32161000

Quality Level

200

species reactivity

mouse

manufacturer/tradename

Milliplex®

assay range

accuracy: 90-99%
sensitivity: 0.005-0.190 ng/mL
(MinDC+2SD)
standard curve range: 0.005-5 ng/mL
(Lipocalin-2/NGAL)
standard curve range: 0.01-10 ng/mL
(Osteopontin (OPN))
standard curve range: 0.04-40 ng/mL
(EGF)
standard curve range: 0.05-50 ng/mL
(Cystatin C)
standard curve range: 0.2-250 ng/mL
(Clusterin)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
HKI1MAG-99KHKI2MAG-99KCKT1MAG-97K
MILLIPLEX® Mouse Kidney Injury Magnetic Bead Panel 2 - Toxicity Multiplex Assay The analytes available for this multiplex kit are: Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, Osteopontin (OPN) (for urine samples) or Clusterin, Cystatin C, Lipocalin-2/NGAL, Osteopontin (OPN) (for serum/plasma samples).

Millipore

MKI2MAG-94K

MILLIPLEX® Mouse Kidney Injury Magnetic Bead Panel 2 - Toxicity Multiplex Assay

MILLIPLEX® Human Kidney Injury Magnetic Bead Panel 1 - Toxicity Multiplex Assay The analytes available for this multiplex kit are: Calbindin, Collagen IV, Fatty Acid Binding Protein 1 (FABP1), GSTα, IP-10, Kidney Injury Molecule-1 (KIM-1), Renin, TFF-3, TIMP-1.

Millipore

HKI1MAG-99K

MILLIPLEX® Human Kidney Injury Magnetic Bead Panel 1 - Toxicity Multiplex Assay

MILLIPLEX® Human Kidney Injury Magnetic Bead Panel 2 - Toxicity Multiplex Assay The analytes available for this multiplex kit are: α-1-Microglobulin, Albumin, Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, and Osteopontin (OPN).

Millipore

HKI2MAG-99K

MILLIPLEX® Human Kidney Injury Magnetic Bead Panel 2 - Toxicity Multiplex Assay

MILLIPLEX® Canine Kidney Toxicity Expanded Magnetic Bead Panel 1, CKT1MAG-97K The analytes available for this multiplex kit are: Clusterin, Cystatin C, Kidney Injury Molecule-1 (KIM-1), IL-8, Lipocalin-2/NGAL, MCP-1, Osteopontin (OPN).

Millipore

CKT1MAG-97K

MILLIPLEX® Canine Kidney Toxicity Expanded Magnetic Bead Panel 1, CKT1MAG-97K

manufacturer/tradename

Milliplex®

manufacturer/tradename

Milliplex®

manufacturer/tradename

Milliplex®

manufacturer/tradename

Milliplex®

assay range

accuracy: 90-99%, sensitivity: 0.005-0.190 ng/mL
(MinDC+2SD), standard curve range: 0.005-5 ng/mL
(Lipocalin-2/NGAL), standard curve range: 0.01-10 ng/mL
(Osteopontin (OPN)), standard curve range: 0.04-40 ng/mL
(EGF), standard curve range: 0.05-50 ng/mL
(Cystatin C), standard curve range: 0.2-250 ng/mL
(Clusterin)

assay range

accuracy: 73-117%, sensitivity: 0.010-6.473 ng/mL
(MinDC = 2SD), standard curve range: 0.005-5 ng/mL
(IP-10), standard curve range: 0.02-25 ng/mL
(Renin), standard curve range: 0.05-50 ng/mL
(GSTα), standard curve range: 0.05-50 ng/mL
(KIM-1), standard curve range: 0.10-100 ng/mL
(TIMP-1), standard curve range: 0.20-200 ng/mL
(Calbindin), standard curve range: 0.34-350 ng/mL
(Collagen IV), standard curve range: 0.49-500 ng/mL
(TFF-3), standard curve range: 5.86-6,000 ng/mL
(FABP1), inter-assay cv: <15%
intra-assay cv: <10%

assay range

accuracy: 95-109%, sensitivity: 0.015-5.359 ng/mL
(MinDC = 2SD), standard curve range: 0.01-10 ng/mL
(EGF), standard curve range: 0.02-20 ng/mL
(Lipocalin-2/ NGAL), standard curve range: 0.20-200 ng/mL
(Cystatin C), standard curve range: 0.59-600 ng/mL
(Osteopontin (OPN)), standard curve range: 0.98-1,000 ng/mL
(α-1-Microglobulin), standard curve range: 3.91-4,000 ng/mL
(Albumin), standard curve range: 4.88-5,000 ng/mL
(Clusterin), inter-assay cv: <20%
intra-assay cv: <10%

assay range

accuracy: 89-107%, sensitivity: 0.005-0.630 ng/mL
(All other analytes; MinDC +2SD), sensitivity: 0.670 pg/mL
(KIM-1; MinDC +2SD), standard curve range: 0.01-10 ng/mL
(Cystatin C), standard curve range: 0.01-10 ng/mL
(Osteopontin), standard curve range: 0.03-20 ng/mL
(Lipocalin-2/NGAL), standard curve range: 0.07-50 ng/mL
(IL-8), standard curve range: 0.07-50 ng/mL
(MCP-1), standard curve range: 1.0-700 pg/mL
(KIM-1), standard curve range: 1.4-1,000 ng/mL
(Clusterin)

technique(s)

multiplexing: suitable

technique(s)

multiplexing: suitable

technique(s)

multiplexing: suitable

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

detection method

fluorometric (Luminex xMAP)

detection method

fluorometric (Luminex xMAP)

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

shipped in

wet ice

shipped in

wet ice

shipped in

wet ice

General description

Maintenance of physiological balance in the body is attributed in part to normal kidney function. An altered kidney function due to injury, drug toxicity or kidney failure may be life threatening. There are multiple risk factors for kidney injury including age, hypertension, diabetes mellitus, heart failure and liver failure. On the other hand, drug induced damage to the kidney results from drug excretion. Traditional markers for assessing renal toxicity, such as blood urea nitrogen (BUN) and serum creatinine, are insensitive and non-specific. Although both are direct measurements of renal function, increases in serum concentrations of these biomarkers occur only after substantial renal injury. Specificity and earlier detection of kidney injury is vital. For improved detection of acute nephrotoxicity, a panel of novel urinary kidney biomarkers has been identified and validated for preclinical studies in relevant animal species. We provide valuable research assays to investigate multiple biomarkers of kidney injury in mouse urine samples using the Luminex® xMAP® instrument platform.

The MILLIPLEX® Mouse Kidney Injury Bead Panel 2 contains all the components necessary to measure the following five biomarkers in any combination using Luminex® xMAP® technology: Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, Osteopontin (OPN). The kit uses a 96-well format, contains a lyophilized standard cocktail, two quality controls and can measure up to 38 urine samples in duplicate.

Panel Type: Toxicity

Specificity

There was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes within a panel.

Application

  • Analytes: Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, Osteopontin (OPN)
  • Recommended Sample type: urine
  • Recommended Sample dilution: 1:1,000
  • Assay Run Time: overnight
  • Research Category: Toxicity

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Packaging

Everything you need in a single kit.

Storage and Stability

Recommended storage for kit components is 2 - 8°C.

Other Notes

Please contact Technical Service for linearity of dilution.
Sensitivity: Please see kit protocol for individual assay sensitivities.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Target Organs

Respiratory Tract

Storage Class Code

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (Example: T1503).

Example:

T1503
Product Number
-
25G
Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Karima Relizani et al.
Molecular therapy. Nucleic acids, 8, 144-157 (2017-09-18)
Antisense oligonucleotides (AONs) hold promise for therapeutic splice-switching correction in many genetic diseases. However, despite advances in AON chemistry and design, systemic use of AONs is limited due to poor tissue uptake and sufficient therapeutic efficacy is still difficult to
Lucía Echevarría et al.
Methods in molecular biology (Clifton, N.J.), 2434, 371-384 (2022-02-26)
Antisense oligonucleotides (ASO) therapeutics hold great promise for the treatment of numerous diseases, and several ASO drugs have now reached market approval, confirming the potential of this approach. However, some candidates have also failed, due to limited biodistribution/uptake and poor
Karima Relizani et al.
Nucleic acids research, 50(1), 17-34 (2021-12-12)
Tricyclo-DNA (tcDNA) is a conformationally constrained oligonucleotide analog that has demonstrated great therapeutic potential as antisense oligonucleotide (ASO) for several diseases. Like most ASOs in clinical development, tcDNA were modified with phosphorothioate (PS) backbone for therapeutic purposes in order to
Philippine Aupy et al.
Molecular therapy. Nucleic acids, 19, 371-383 (2019-12-28)
Tricyclo-DNA (tcDNA) antisense oligonucleotides (ASOs) hold promise for therapeutic splice-switching applications and the treatment of Duchenne muscular dystrophy (DMD) in particular. We have previously reported the therapeutic potential of tcDNA-ASO in mouse models of DMD, highlighting their unique pharmaceutical properties

Related Content

Nephrotoxicity Analysis with Kidney Toxicity Multiplex Assays | MILLIPLEX® Assays

Novel kidney toxicity biomarkers expand options for acute nephrotoxicity detection. Multiplex assays measure multiple renal damage biomarkers in small sample volumes, minimizing time and costs. See how MILLIPLEX® multiplex kidney toxicity assays detected vancomycin-induced subacute nephrotoxicity in rat models.

Multiplex Toxicity Assays | MILLIPLEX® Assays

Multiplex toxicity assays enable researchers to simultaneously measure multiple toxicity biomarkers of various organs to gain a better understanding of toxicity. Explore how MILLIPLEX® multiplex toxicity assays are advancing research on liver injury, kidney toxicity, genotoxicity, and more.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service